Open Access Open Badges Case report

3-M syndrome associated with growth hormone deficiency: 18 year follow-up of a patient

Cristina Meazza1, Ekkehard Lausch2, Sara Pagani1, Elena Bozzola3, Valeria Calcaterra1, Andrea Superti-Furga4, Margherita Silengo5 and Mauro Bozzola1*

Author Affiliations

1 Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Piazzale C. Golgi 2, Pavia 27100, Italy

2 Division of Paediatric Genetics, Centre for Paediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany

3 U.O. di Pediatria Generale e Malattie Infettive, Ospedale Pediatrico Bambino Gesù, Roma, Italy

4 University of Lausanne, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

5 Department of Paediatrics, University of Torino, Torino, Italy

For all author emails, please log on.

Italian Journal of Pediatrics 2013, 39:21  doi:10.1186/1824-7288-39-21

Published: 21 March 2013


3-M syndrome is a rare autosomal recessive disorder that causes short stature, unusual facial features and skeletal abnormalities. Mutations in the CUL7, OBSL1 and CCDC8 genes could be responsible for 3-M syndrome.

Here we describe the growth and evolution of dismorphic features of an Italian boy with 3-M syndrome and growth hormone deficiency (GHD) from birth until adulthood. He was born full term with a very low birth weight (2400 g=−3.36 standard deviation score, SDS) and length (40.0 cm =−6.53 SDS). At birth he presented with a broad, fleshy nose with anteverted nostrils, thick and patulous lips, a square chin, curvilinear shaped eyebrows without synophrys, short thorax and long slender bones. Then, during childhood tall vertebral bodies, hip dislocation, transverse chest groove, winged scapulae and hyperextensible joints became more evident and the diagnosis of 3-M syndrome was made; this was also confirmed by the finding of a homozygous deletion in exon 18 of the CUL7 gene, which has not been previously described.

The patient also exhibited severe GHD (GH <5 ng/ml) and from the age of 18 months was treated with rhGH. Notwithstanding the early start of therapy and good compliance, his growth rate was always very low, except for the first two years of treatment and he achieved a final height of 132 cm (−6.42 SDS).

3-M syndrome; Growth hormone deficiency; CUL-7 gene mutation